scispace - formally typeset
Open AccessJournal ArticleDOI

A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Reads0
Chats0
TLDR
This is the first non-infectious vaccine conferring complete protective immunity up to 8 weeks after vaccination and demonstrates the potential of 'next-generation' DNA vaccines.
About
This article is published in Vaccine.The article was published on 2011-09-09 and is currently open access. It has received 34 citations till now. The article focuses on the topics: Vaccination & DNA vaccination.

read more

Citations
More filters
Journal ArticleDOI

Cytomegalovirus Vaccines: Current Status and Future Prospects

TL;DR: An overview of HCMV vaccine candidates in various stages of development is provided, as well as an update on the current status of ongoing clinical trials.
Journal ArticleDOI

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine

TL;DR: Evidence is presented that various SP-D-TNFSFL fusion constructs can enhance immune responses following DNA vaccination with HIV-1 Gag expression plasmid, which supports the continued evaluation of SP- D-TN FSFL fusion proteins as molecular adjuvants for DNA and/or viral vector vaccines.
Journal Article

Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.

TL;DR: Although the protective role of cell-mediated immunity has been repeatedly documented, while the protective effect of (mostly neutralizing) antibodies remains partly to be documented, a vaccine stimulating both arms of the immune response would likely confer the highest level of protection against HCMV infection/disease in both H CMV-seronegative and -seropositive individuals.
Journal ArticleDOI

Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine

TL;DR: This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases.
References
More filters
Journal ArticleDOI

Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection

TL;DR: Much of the CD8 T cell expansion seen during viral infection represents antigen-specific cells and warrants a revision of current thinking on the size of the antiviral response.
Journal ArticleDOI

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

TL;DR: Evidence is presented here that the interaction of cytotoxic T cells with other somatic cells budding4–5 lymphocytic choriomeningitis (LCM) virus is similarly restricted.
Journal ArticleDOI

Immunological Memory and Protective Immunity: Understanding Their Relation

TL;DR: The current understanding of the cellular basis of immune memory is reviewed and the relative contributions made to protective immunity by memory and effector T and B cells are examined.
Journal ArticleDOI

Requirement for CD4 T cell help in generating functional CD8 T cell memory

TL;DR: Results demonstrate a previously undescribed role for CD4 help in the development of functional CD8 memory and show that depletion of CD4 cells during the recall response has minimal effect, whereas depletion during the priming phase leads to reduced responses to reinfection.
Journal ArticleDOI

Massive Expansion of Antigen-Specific CD8+ T Cells during an Acute Virus Infection

TL;DR: Analysis of the effect of the monospecific TCR-transgenic T cells on the host response to three LCMV epitopes suggests that CTL precursors compete for sites on the APC in an epitope-specific fashion and that this competition determines the specificity of the response.
Related Papers (5)
Trending Questions (1)
How long does it take to make antibodies after first Covid vaccine?

This is the first non-infectious vaccine conferring complete protective immunity up to 8 weeks after vaccination and demonstrates the potential of 'next-generation' DNA vaccines.